Introduction
Cigarette smoking is one of the largest preventable causes of death and disease in developed countries. Nevertheless, approximately 24% of adults were current smokers in the United States in 1997 (Centers for Disease Control and Prevention, 2002 . Tobacco-related disease is responsible for approximately 440 000 deaths annually and results in approximately $160 billion in health-related costs in the United States (Centers for Disease Control and Prevention, 2002) . Moreover, by 2020, tobacco-related disease is projected to become the largest single health problem worldwide, resulting in approximately 8.4 million deaths each year (Murray and Lopez, 1997) . Despite the well-known negative health consequences associated with the tobacco smoking habit, only about 10% of smokers who attempt to quit annually remain abstinent after 1 year.
Nicotine contained in tobacco smoke is one of the most widely consumed psychotropic agents in the world. Nicotine is considered the primary reinforcing component of tobacco responsible for addiction in human smokers (Stolerman and Jarvis, 1995) . Nevertheless, many other components of tobacco smoke may also contribute to tobacco addiction, perhaps by increasing the reinforcing effects of nicotine (Fowler et al., 1996; Agatsuma et al., 2006; Guillem et al., 2006; Rose, 2006; Villegier et al., 2007; Guillem et al., 2008) . Consistent with a role for nicotine in the tobacco smoking habit, nicotine elicits a positive affective state in both human smokers and nonsmokers (Barr et al., 2008; Sofuoglu et al., 2008) and is self-administered by humans (Henningfield et al., 1983; Rose et al., 2003; Sofuoglu et al., 2008) , nonhuman primates (Goldberg et al., 1981; Le Foll et al., 2007) , and rodents (Corrigall and Coen, 1989; Picciotto et al., 1998; Watkins et al., 1999) . Importantly, the tobacco smoking habit may depend not only on the positive reinforcing actions of nicotine, but also on escape from the aversive consequences of nicotine withdrawal (i.e. negative reinforcement) (Doherty et al., 1995; Kenny and Markou, 2001; George et al., 2007) . Prolonged tobacco consumption can result in the development of nicotine dependence, and smoking cessation can elicit an aversive withdrawal syndrome in nicotine-dependent human smokers (Shiffman and Jarvik, 1976; Hughes et al., 1991) . The duration and severity of nicotine withdrawal may predict relapse in abstinent human smokers (Piasecki et al., 1998 (Piasecki et al., , 2000 (Piasecki et al., , 2003 . Furthermore, the efficacy of nicotine replacement therapy for smoking cessation may be related to the reduction of nicotine withdrawal in abstinent smokers, at least in certain individuals (Fagerstrom, 1988; Sachs and Leischow, 1991) .
Neuronal nicotinic acetylcholine receptors (nAChRs) are the primary site of action for nicotine in the brain. As such, nAChRs are considered important targets for the development of therapeutic agents that may facilitate smoking cessation efforts. For example, varenicline (Chantix; Pfizer, New York, USA), a partial agonist at nAChRs, was approved recently by the US Food and Drug Administration (FDA) as a pharmacological aid for smoking cessation and is effective in preventing relapse to tobacco smoking during abstinence (Gonzales et al., 2006; Jorenby et al., 2006; West et al., 2007) . Thus, identification of the nAChRs at which nicotine acts in the brain to elicit its reinforcing effects, and also the nAChRs at which nicotine acts to induce the development of dependence and expression of withdrawal, may provide valuable insights into the neurobiology of the nicotine habit in human tobacco smokers and facilitate the development of novel therapeutic strategies for the treatment of tobacco addiction (e.g., see Domino, 2000) . However, little is known regarding the nAChR subtypes that regulate the reinforcing actions of nicotine in vivo. This lack of knowledge reflects an absence of small-molecule ligands that are selective for specific nAChR subtypes. Although many current nAChR ligands may be more selective for certain nAChR subtypes, they nonetheless exhibit binding affinities for other nAChR subtypes. Therefore, attributing any particular behavioral effect of nicotine to an action at a discrete nAChR subtype is difficult. The construction of genetically modified mice with null mutations in the genes that encode individual nAChR subunits offers a promising approach to identifying the nAChR subtypes that regulate the actions of nicotine in vivo and the contribution of specific nAChR subtypes in physiology and disease. Indeed, as summarized in Table 1 , nAChR mutant mice have been used extensively over recent years to examine the roles of nAChR subunits in a broad range of physiological processes. Although the use of knockout mice is a promising strategy, certain limitations should be taken into account with interpretation of the data. First of all, the animal has been without the gene for the duration of development, and physiological compensation may have occurred. For example, the a7 knockout exhibits increased expression of both the a3 and a4 subunits (Yu et al., 2007) , whereas the b3 knockout displays decreased a6 subunit expression (Gotti et al., 2005) . Second, primary effects on behavior may be noted in secondary measures. For instance, decreased open field activity may be indicative of increased anxiety, rather than decreased locomotion. In this respect, it is important to use varying techniques and behavioral measures to fully address the research questions. Until the development of more sophisticated methods that afford precise control over anatomical and temporal factors, as well as the pharmacological development of specific ligands, knockout mice remain an essential tool in defining the mechanisms underlying addiction processes. In this review, we will outline the progress that has been made in identifying nAChR subunit components of the nicotinic receptors that regulate the rewarding properties of nicotine, as well as those that contribute to nicotine dependence and withdrawal. In particular, we will highlight those studies that have used mice with genetic modifications of nAChR subunits.
Strong epidemiological evidence suggests that the rate of tobacco dependence is far higher in individuals who suffer from psychiatric illnesses, such as anxiety disorders, depression, or schizophrenia, compared with the rate of tobacco dependence observed in the general population (Dani and Harris, 2005) . Thus, the increased susceptibility to tobacco addiction in patients with comorbid psychiatric illness may reflect disease-associated deficits in nAChR signaling. An alternative, but not mutually exclusive, explanation is that smoking represents an attempt at self-medication of disease-associated symptoms through the consumption of nicotine (see below for more detailed discussion of these possibilities). On the basis of these observations, the role of nAChRs in psychiatric disorders associated with high levels of tobacco addiction is an important consideration because such knowledge may reveal important clues regarding the role and identity of nAChR subtypes in nicotine dependence and disease states. We will also briefly discuss recent advances in our knowledge related to the role of nAChRs in anxiety disorders, depression, and schizophrenia, again focusing on data generated from mice with genetic modifications of nAChR subunits. Throughout this review and consistent with the accepted nomenclature, the asterisk (*) annotation beside a specific subunit denotes a nAChR that contains the indicated subunit but for which the complete subunit composition is unknown. the M2 domain lining the pore (Unwin, 1995 (Unwin, , 2005 Grosman and Auerbach, 2000; Miyazawa et al., 2003; Taly et al., 2005; Cymes and Grosman, 2008) . Domains M1 and M3 shield M2 from the surrounding lipid bilayer, and M4 is the outermost and most lipid-exposed segment (Unwin, 1995 (Unwin, , 2005 Grosman and Auerbach, 2000; Miyazawa et al., 2003; Taly et al., 2005; Cymes and Grosman, 2008) . Upon nAChR activation by an endogenous agonist (e.g. acetylcholine) or exogenous agonist (e.g. nicotine), the domains of each of the five nAChR subunits rearrange such that the central pore opens and permits cationic trafficking. The nAChR a subunit exists in nine isoforms (a2-a10), whereas the neuronal b subunit exists in three isoforms (b2-b4) (Chini et al., 1994; Elgoyhen et al., 2001; Le Novere et al., 2002; Lips et al., 2002) . The receptor subunits arrange in various combinations to form functionally distinct pentameric nAChR subtypes, with a and b subunits combining with a putative stoichiometry of 2a : 3b (Deneris et al., 1991; Sargent, 1993) (Fig. 1 ). However, accumulating evidence suggests that a 3a: 2b stoichiometry may be common in the central nervous system (CNS) (see later sections). The a7, a8, and a9 subunits usually form homopentameric complexes composed of five a subunits and no b subunits, with only the a7 pentameric nAChR present in the central nervous system (CNS).
Owing to the large number of subunits, potentially many nAChR subtypes can exist, each composed of various combinations of a and b subunits. However, the assembly of nAChRs is a tightly regulated process that requires appropriate subunit interactions to produce functional nAChRs. As a result, the number of functional nAChR subtypes seems to be far less than that which could be generated theoretically (Table 2) . As noted above, due to a lack of receptor agonists and antagonists with selectivity for individual nAChR subunits, the precise combinations of nAChR subunits that constitute functional neuronal nAChR subtypes in vivo are unknown. However, recent studies have begun to identify the nAChR subunits expressed by individual neurons in the brain. For example, single-cell reverse transcription polymerase chain reaction (RT-PCR) coupled with patch-clamp recordings suggests that approximately 90-100% of neurons located in the medial habenula (MH) express the a3, a4, a5, b2, and b4 nAChR subunits (Sheffield et al., 2000) . In contrast, only about 40% of MH neurons express the a6, a7, and b3 subunits, whereas the a2 subunit was not found (Sheffield et al., 2000) . Similar techniques revealed a significant coexpression of a3 and a5, a4 and b2, a4 and b3, a7 and b2, b2 and b3, and b3 and b4 within individual neurons in the rat hippocampus (Sudweeks and Yakel, 2000) . Such investigations eventually may reveal the subunit composition of nAChR subtypes that are expressed by distinct cell populations.
In-situ hybridization has been used to examine the distribution of messenger RNAs (mRNAs) for each nAChR subunit throughout the CNS of humans, nonhuman primates, rats, and mice (Table 3 ) (for review, see Drago et al., 2003) . These experiments demonstrate marked differences in the distribution and density of the various subunits throughout the mammalian brain. Overall, a4, b2, and a7 subunits are the most widely expressed, whereas a2, a5, a6, b3, and b4 subunits demonstrate a more restricted expression profile Table 2 ). In addition, although their relative densities may vary, considerable overlap exists in the expression profiles of the a4 and b2 subunits, suggesting that a4b2* nAChRs represent a major subtype of nAChR in the brain. Importantly, a2, a3, a4, a5, a6, a7, b2, and b3 subunits are expressed in brain regions that are known to play a role in the reinforcing effects of addictive drugs and in the cognitive and emotional deficits associated with various neuropsychiatric disorders. Indeed, these nAChR subunits are abundantly expressed in the amygdala, nucleus accumbens (NAc), ventral tegmental area (VTA), hippocampus, and throughout cortical areas (Table 3) .
Nicotinic receptors within the CNS are situated mainly on presynaptic terminals (Wonnacott, 1997) but are also found at somatodendritic, axonal, and postsynaptic locations (for review, see Sargent, 1993) . One of the predominant roles of nAChRs in the CNS has been proposed to be the modulation of transmitter release as heteroreceptors (Wonnacott, 1997) . Accordingly, nicotine has been shown to stimulate the release of most neurotransmitters in the brain, including dopamine, glutamate, g-aminobutyric acid (GABA), norepinephrine, and serotonin (Carboni et al., 2000; Kenny et al., 2000b; Mansvelder and McGehee, 2000; Fu et al., 2003) . Importantly, although not discussed in detail in this review, the stimulatory action of nicotine on neurotransmitter release and on cell excitability is hypothesized to regulate many of the behavioral actions of nicotine in human tobacco smokers (for review, see Benowitz, 2008) .
Neurobiological mechanisms of nicotine reinforcement
To identify the subunit composition of the nAChRs that regulate the reinforcing effects of nicotine, it is important to have an understanding of the neurobiological mechanisms by which nicotine acts in the brain to elicit its effects. Attention can thereby be focused on identifying those nAChRs located within reinforcement-related neural circuitries. It is important to note that dynamic rearrangement of the subunit content of constitutively expressed nAChRs in reinforcement circuitries may occur upon repeated exposure to rewarding doses of nicotine. Chronic exposure to nicotine in vitro robustly upregulates nAChRs and nicotine dependence Fowler et al. 463 a4* and b2* nAChRs, whereas the a7, a3*, and b4* nAChRs are more resistant to upregulation (for review, see Gentry and Lukas, 2002) . Consistent with this invitro observation, increased expression of a4b2* receptors has been found in postmortem brain tissues of human smokers (Benwell et al., 1988; Breese et al., 1997) . The a5 nAChR subunit seems to play an important modulatory role within nAChRs. In Xenopus oocytes, inserting the a5 subunit into a4b2, a3b2, or a3b4 nAChRs increases receptor desensitization in response to nicotine (Ramirez-Latorre et al., 1996; Wang et al., 1996) . Interestingly, the a3a5b2 subunit combination exhibits an increased affinity for nicotine compared with the a3b2 subtype , a modification that, in vivo, could result in altered susceptibility to nicotine reward and vulnerability to tobacco addiction. Thus, nicotine-induced alterations in the expression of nAChR subunits may have a profound impact on the function of nAChRs in brain reward circuitries that may contribute to tobacco addiction. However, since current knowledge regarding nicotine-induced alterations in the subunit content of nAChRs in vivo is very limited, the contribution of this process to tobacco addiction is not reviewed in detail here.
Similar to other major drugs of abuse, nicotine enhances mesocorticolimbic dopamine transmission, and this action is hypothesized to play an important role in the positive reinforcing effects of nicotine (Merlo-Pich et al., 1997; Pidoplichko et al., 1997; Balfour et al., 2000; Koob and Le Moal, 2006) . In-vivo microdialysis studies have demonstrated that subcutaneous injections of nicotine (0.1 mg/kg) or cocaine (3 mg/kg) increase accumbal dopamine release by a similar magnitude (Zernig et al., 1997) . The powerful impact of nicotine on brain reward path-ways is further evidenced by a significant lowering of intracranial self-stimulation (ICSS) thresholds in rats in response to intravenously self-administered nicotine. Indeed, although rats self-administer relatively low numbers of nicotine infusions compared with the amount of cocaine consumed under similar conditions, rats nevertheless titrate their nicotine intake to a level that significantly lowers ICSS thresholds, with a magnitude of effect comparable with that induced by self-administered heroin or cocaine (Kenny et al., 2003 Kenny, 2007) . Taken together, these observations suggest that nicotine can impact brain reward circuitries and facilitate their activity in a manner similar to other major drugs of abuse.
Whole-cell electrophysiological and in-vivo microdialysis studies have demonstrated that systemic or direct VTA administration of nicotine increases the firing rate of mesoaccumbens dopamine neurons and increases dopamine release in the NAc (Andersson et al., 1981; Di Chiara and Imperato, 1988; Benwell and Balfour, 1992) , particularly the shell region of the NAc (Pontieri et al., 1996) , but also in other mesolimbic terminal regions, such as the bed nucleus of the stria terminalis (Carboni et al., 2000) . Systemic nicotine-induced dopamine release in the NAc can be blocked by infusion of the nAChR antagonist mecamylamine into the VTA but not into the NAc; however, site-specific infusion of nicotine into the VTA or NAc can increase extracellular accumbal dopamine levels (Nisell et al., 1994) . Thus, nicotine likely acts preferentially in the VTA to increase mesoaccumbens dopamine transmission but may also act in the striatum to modulate dopamine transmission. Furthermore, systemic administration of dopamine receptor antagonists (Corrigall and Coen, 1991) or lesions of the NAc (Corrigall et al., 1992) m Rotarod performance k Passive avoidance latency Marubio and Paylor (2004) b2b4
Dilated pupils do not contract to light Impaired bladder contractility, enlarged bladder, dribbling urination, urinary tract infection, bladder stones Lethal at 1-3 weeks postnatal attenuates the reinforcing effects of nicotine, reflected in decreased intravenous nicotine self-administration in rats. Infusion of the nAChR antagonist dihydro-b-erythroidine (DHbE) directly into the VTA decreases nicotine self-administration in rats (Corrigall et al., 1994) . Accumulating evidence suggests that, in addition to the direct stimulatory action of nicotine at postsynaptic nAChRs located on dopamine-containing VTA neurons, nicotine may increase mesoaccumbens dopamine transmission by indirect actions involving glutamate and GABA transmission in the VTA. Indeed, nicotine activates nAChRs located on VTA glutamate terminals (Grillner and Svensson, 2000; Mansvelder and McGehee, 2000; Jones and Wonnacott, 2004) , and thereby induces a persistent increase in glutamate transmission in this brain site (Fu et al., 2000; Grillner and Svensson, 2000; Schilstrom et al., 2000) . In turn, this enhanced glutamate transmission stimulates postsynaptic glutamate receptors located on dopamine-containing neurons, thereby increasing their burst firing (Kalivas, 1993; Hu and White, 1996; Schilstrom et al., 1998; Fu et al., 2000; Mansvelder and McGehee, 2000; Kosowski et al., 2004) . In addition, nicotine activates nAChRs located on GABAergic neurons in the VTA (Mansvelder et al., 2002) , resulting in a transient increase in inhibitory GABAergic transmission. nAChRs located on GABAergic neurons in the VTA, Graphical representation of the nicotinic acetylcholine receptor (nAChR). (a) nAChRs are formed by the association of five distinct membrane-spanning subunits (a and b subunits), with each individual subunit composed of four membrane-spanning helices (M1-M4 domains). These membrane-spanning domains are arranged in concentric layers around a central aqueous pore with the M2 domain lining the pore. (b) The nAChR a subunit exists in nine isoforms (a2-a10), whereas the neuronal b subunit exists in three isoforms (b2-b4). Upon receptor activation, the domains of each subunit in the pentameric nAChR rearrange such that the central pore opens and permits cationic trafficking. (c) The exogenous nAChR agonist nicotine binds at the interface between the a and b subunits in heteromeric nAChRs to activate the receptor. however, seem to be very sensitive to nicotine-induced desensitization, and following nicotine-induced activation may become nonfunctional for prolonged periods of time (Mansvelder et al., 2002) . Additionally, nAChRs located presynaptically on cholinergic fibers into the VTA may also regulate mesoaccumbens dopamine transmission (Maskos, 2008) . Identification of the subunit composition of nAChRs in the VTA, especially those located on dopaminergic, glutaminergic, GABAergic, and cholinergic neurons, is likely to provide important insights to the identity of the nAChR subtypes that regulate nicotine reinforcement. Similarly, identification of the nAChR subunits expressed in terminal brain regions of VTA dopaminergic neurons, such as the NAc, may also provide important clues to the nAChR subtypes that regulate nicotine reinforcement. The data outlined below describe recent advances in our understanding of the nAChR subunits that are expressed in the VTA and NAc and highlight the utility of nAChR genetically modified mice in this regard. Importantly, although not reviewed in detail here, nicotine exerts actions in reward-relevant brain regions other than the VTA and NAc, and extramesolimbic nAChRs also play a central role in nicotine reinforcement .
Nicotinic acetylcholine receptor subunits that regulate the positive reinforcing effects of nicotine: in-vitro evidence
On the basis of accumulating evidence that the VTA is a core brain site regulating behavioral actions of nicotine with relevance to addiction, much effort has been directed toward elucidating the nicotinic subunits expressed in this site. Charpantier et al. (1998) used RT-PCR to analyze mRNA content of individual nAChR subunits in the VTA following unilateral lesions of the mesoaccumbens system in rats. In contrast to the unlesioned side, mRNA signals for a2, a3, a5, a6, a7, and b4 subunits were absent in the VTA of the lesioned hemisphere (Charpantier et al., 1998) . These nAChR subunits, therefore, may be expressed preferentially in dopaminergic neurons that originate in the VTA. Interestingly, mRNA for a4, b2, and b3 subunits was detected after the dopamine lesion (Charpantier et al., 1998) , suggesting that these subunits may be expressed in both dopaminergic, as well as GABAergic, neurons in the VTA. Klink et al. (2001) used RT-PCR and single-cell electrophysiological recordings in wild-type and nAChR knockout mice to investigate subunit composition of nAChR subtypes expressed in the VTA. Almost 100% of cells in the VTA (i.e. dopaminergic and GABAergic) expressed mRNA for the a4 and b2 subunit (Klink et al., 2001) , suggesting that these subunits may be incorporated into many nAChR subtypes in this area. Approximately 90% of dopaminergic cells and 20% of GABAergic cells in the VTA contained b3 nAChR subunits (Klink et al., 2001) . Similarly, approximately 70% of dopaminergic neurons in the VTA expressed a5 nAChR mRNA, with a much lower proportion of GABAergic cells (< 20%) expressing this subunit (Klink et al., 2001) . Approximately 75% of dopaminergic cells in the VTA expressed a6 nAChR subunits, compared with about 10% of GABAergic cells. Around 40% of both dopamine and GABAergic cells expressed mRNA for the a7 nAChR subunit (Klink et al., 2001) . A relatively low concentration of b4 mRNA was observed in VTA cells, consistent with the high concentrations of this subunit that are restricted to the MH and interpeduncular nucleus. Therefore, the majority of dopamine neurons in the VTA expressed a4, a5, a6, b2, and b3 mRNA, whereas the majority of GABA neurons expressed a4 and b2 subunits, with a7 subunits demonstrating a similar incidence in both cell types. Interestingly, in the VTA, electrophysiological analyses suggested that the only currents elicited by acetylcholine in b2 knockout mice were regulated by a7 pentameric nAChRs subunit (Klink et al., 2001) . In a4 knockout mice, acetylcholine-evoked currents were qualitatively similar but quantitatively smaller than those observed in wildtype mice (Klink et al., 2001) . Finally, in a7 knockout mice, acetylcholine-evoked currents were qualitatively and quantitatively similar to those observed in wild-type mice, with the exception that putative a7-mediated currents were absent. On the basis of the above, three subtypes of pentameric nAChRs were proposed to be putatively functional on VTA dopaminergic neurons: a4a6a5(b2) 2 , (a4) 2 a5(b2) 2 , and (a7) 5 . On VTA GABAergic neurons, two nAChR subtypes predominated: (a4) 3 (b4) 2 and (a7) 5 .
Interestingly, although mRNA for the b3 nAChR is abundant in the VTA, this subunit does not seem to contribute to functional nAChRs in this brain site. Instead, the b3 subunit may be targeted to terminal domains in the NAc where it contributes to the stimulatory effects of nicotine on accumbal dopamine transmission. Immunocytochemical analyses demonstrated that b3 subunits are transported to the projection areas of VTA neurons (Forsayeth and Kobrin, 1997) and that the striatum has high b3 protein concentrations (Forsayeth and Kobrin, 1997; Reuben et al., 2000) . Using experimental approaches similar to those described above, much progress has been made in elucidating putative nAChR subtypes in the striatum that regulate the stimulatory effects of nicotine on dopamine transmission in this brain region. This work has been facilitated by combining data generated from nAChR mutant mice with classical pharmacological approaches. In particular, the discovery that the novel nAChR antagonist a-conotoxin MII (a-CtxMII) can attenuate, but not fully block, the stimulatory effects of nicotine on striatal dopamine release suggested that at least two subpopulations of nAChRs regulate the actions of nicotine, a finding that has proven to be very useful in characterizing putative nAChRs and nicotine dependence Fowler et al. 467 nAChR subtypes in the striatum. Zoli et al. (2002) used a-CtxMII combined with immunoprecipitation and targeted brain lesion to provide evidence that four species of nAChRs may be expressed on the terminals of mesoaccumbens dopamine neurons in the striatum that contain the following subunits: a4b2*, a4a5b2*, a4a6b2b3*, or a6b2b3* . Interestingly, by using a-CtxMII and various nAChR ligands in combination with nAChR knockout mice, Salminen et al. (2004) similarly concluded that a4b2*, a4a5b2*, a4a6b2b3*, and a6b2b3* nAChRs may be located on dopamine terminals in the striatum, where they can regulate the stimulatory effects of nicotine on mesoaccumbens dopamine transmission. In addition, two further putative nAChR subtypes were identified in these studies: a6b2b3* and a6b2* (for recent review, see Grady et al., 2007) . The effects of acetylcholine-evoked dopamine release from striatal synaptosomes and nicotine-evoked striatal dopamine release measured by in-vivo microdialysis have been assessed in a4, a6, a4a6, and b2 knockout mice (Champtiaux et al., 2003) . a4b2*, a6b2*, and a4a6b2* nAChRs were shown to be expressed on dopamine terminal fields in the striatum. Additionally, a6b2* nAChRs were found to be functional and sensitive to a-CtxMII inhibition but do not contribute to dopamine release evoked by systemic nicotine administration, and somatodendritic (non-a6) a4b2* nAChRs were posited to be the most likely to regulate nicotine reinforcement (Champtiaux et al., 2003) . Taken together, the above data suggest that a4, a5, a6, b2, and b3 may be important components of functionally expressed nAChR subtypes in the VTA and striatum. These nAChR subunits likely play an important role in regulating nicotine reinforcement processes.
Electrophysiological investigations have also provided important insights into the nAChR subtypes likely to be expressed in the VTA and striatum that may regulate nicotine reinforcement. Initially, Picciotto et al. (1998) found that nicotine increased the discharge frequency of mesencephalic dopaminergic neurons from wild-type but not b2 knockout mice. Mameli-Engvall et al. (2006) extended these findings specifically within dopaminergic VTA neurons; basal levels of firing were decreased and burst firing was absent in VTA dopaminergic neurons from b2 knockout mice. Furthermore, the stimulatory effect of intravenous nicotine on VTA dopamine cells was abolished in b2 knockout mice (Mameli-Engvall et al., 2006) . The role of b2* nAChRs in regulating the effects of endogenous cholinergic transmission on dopamine release from mouse striatal slices also has been assessed (Zhou et al., 2001) . b2 knockout mice were shown to have reduced levels of electrically evoked dopamine release compared with wild-type controls (Zhou et al., 2001) . These electrophysiological data from nAChR knockout mice support the hypothesis that b2* nAChRs play an important role in regulating the effects of nicotine on the neuroanatomical substrates that are implicated in nicotine reinforcement.
Nicotinic acetylcholine receptor subunits that regulate the positive reinforcing effects of nicotine: in-vivo evidence
In addition to the in-vitro approaches described above, in-vivo studies are beginning to shed more direct light on nAChR subunits involved in nicotine reinforcement and dependence processes. Many of the published studies assessing the role of nAChR subtypes in nicotine reinforcement have used the intravenous nicotine selfadministration procedure. This procedure is considered the most direct and reliable measure of the reinforcing properties of drugs of abuse. Indeed, the majority of drugs that are abused by humans are also self-administered by other mammalian species (Weeks, 1962; Wilson and Schuster, 1972; Risner and Jones, 1975; Griffiths and Balster, 1979; Griffiths et al., 1981; Criswell and Ridings, 1983; Donny et al., 1995) . Consistent with a role for nicotine in initiating and maintaining the tobacco smoking habit in humans, nicotine acts as a reinforcer and is self-administered by humans (Harvey et al., 2004) , nonhuman primates (Goldberg et al., 1981) , dogs (Risner and Goldberg, 1983) , and rats (Corrigall and Coen, 1989; Watkins et al., 1999) . Nicotine self-administration produces an inverted U-shaped dose-response curve in all cases, similar to that obtained for other reinforcing drugs such as opiates and cocaine. It is likely that the shape of the nicotine dose-response curve is the result of the competing positive and negative effects of nicotine at different doses. Thus, the increased responding for nicotine over the ascending limb of the curve may reflect the increasing reinforcing effects of nicotine as the unit dose per infusion increases. In contrast, the decreased responding over the descending limb of the curve may reflect increasing aversive properties of nicotine. Consistent with the hypothesis that nicotine may elicit both positive and negative effects, doses of nicotine selfadministered by nonhuman primates can also serve as the substrate for negative reinforcement, and monkeys will work to avoid such intravenous nicotine infusions (Spealman and Goldberg, 1982) . Further, anxiety-like behavior was increased in rats after volitional intravenous selfadministration of nicotine , and benzodiazepine treatment, which counters the aversive properties of nicotine, increased nicotine self-administration in rats (Hanson et al., 1979) . Finally, it is important to note that the nicotine dose-response curve is 'shallow' and 'narrow' compared with that obtained for opiates or cocaine, suggesting that responding for nicotine is relatively insensitive to alterations in the dose available for infusion, and that nicotine is reinforcing over a narrow range of doses only.
Consistent with a role for neuronal nAChRs in regulating nicotine reinforcement, administration of antagonists at neuronal nAChRs decreases nicotine self-administration in nonhuman primates and rats. This decrease in nicotine intake is in contrast to human tobacco smokers, in which there was a transient increase in smoking behavior (Stolerman et al., 1979) or intravenous nicotine selfadministration (Rose et al., 1989) , after antagonist blockade of nAChRs. This finding in rats is also in contrast to findings with other drugs of abuse such as opiates or cocaine, where administration of opioid or dopamine receptor antagonists increased opiate or cocaine intake, respectively. Such compensatory increases in drug intake are likely to occur to counter antagonist-induced reductions in the reward value of unit injections of drugs of abuse. Thus, the net effect of antagonist treatment is usually a rightward shift in the dose-response curve. One possible explanation for the absence of such antagonist-induced compensatory increases in nicotine intake in laboratory animals may be that different subtypes of nAChRs regulate the reinforcing and aversive properties of nicotine, and nAChR antagonists in these animals may selectively block the reinforcing effects of nicotine but not its aversive effects. Such an action of nAChR antagonists would prevent laboratory animals from self-administering compensatory nicotine injections. Whatever the explanation, the net effect of decreasing the reinforcing properties of nicotine in rodents seems to be a shift in the nicotine self-administration dose-response curve downward instead of rightward, resulting in an overall decrease in responding for nicotine at each unit dose of nicotine available. Thus, pharmacological or genetic manipulations that decrease nicotine reinforcement may be expected to result in a decrease in response for nicotine self-administration.
Systemic or intra-VTA administration of the neuronal nAChR antagonist DHbE decreases nicotine self-administration in rats (Corrigall and Coen, 1989; Watkins et al., 1999) . In addition, DHbE reduces the stimulatory effects of nicotine on brain reward systems, demonstrated by attenuated nicotine-induced lowering of ICSS thresholds in rats (Ivanova and Greenshaw, 1997; Harrison et al., 2002) . DHbE is relatively selective for a4* and b2* nAChRs compared with other classes of nAChRs . The novel nAChR ligand SSR591813, considered a partial agonist at nAChRs containing a4 and b2 subunits, decreases nicotine selfadministration in rats (Cohen et al., 2003) . Similarly, the novel nAChR ligand UCI-30002, a partial agonist at a4b2* nAChRs (but also with actions at a7 and a3b4containing nAChRs), also decreases nicotine self-administration in rats (Yoshimura et al., 2007) . Varenicline, a partial agonist at a4b2* nAChRs (but a full agonist at a7* nAChRs) (Mihalak et al., 2006) , dose-dependently decreases nicotine self-administration in rats (Rollema et al., 2007) . Liu et al. (2003) have shown that 5-iodo-A-85380, a putative agonist at b2* nAChRs, is actively self-administered by rats. Full dose-response analyses of these novel drugs should be determined in further studies. Nevertheless, these pharmacological data suggest that a4* and b2* nAChRs play an important role in nicotine reinforcement.
Recent observations in nAChR mutant mice also support the role of these receptor subunits in nicotine addiction.
To date, the reinforcing effects of intravenously selfadministered nicotine have been assessed only in b2 knockout mice (Picciotto et al., 1998; Epping-Jordan et al., 1999) . In these studies, b2 knockout mice and their wildtype counterparts were trained to nose-poke for cocaine under a fixed-ratio 2, time-out 20 s schedule of reinforcement, in which two nose pokes into an 'active' nose-poke hole resulted in an intravenous infusion of cocaine (0.8 mg/kg/infusion) (Picciotto et al., 1998) . Under this schedule of reinforcement, b2 knockout and wild-type mice demonstrated similar levels of responses for cocaine (Picciotto et al., 1998; Epping-Jordan et al., 1999) . However, when cocaine was substituted with nicotine infusions (0.03 mg/kg/infusion), wild-type mice persisted in responding for nicotine, whereas b2 knockout mice rapidly extinguished operant responses, in a manner similar to that observed in wild-type mice when cocaine was substituted with saline (Picciotto et al., 1998; Epping-Jordan et al., 1999) . Most recently, Maskos et al. (2005) used lentivirus-mediated gene transfer to reexpress b2 nAChR subunits in the VTA of b2 knockout mice. In these 'rescued' b2 knockout mice, systemic nicotine administration significantly increased dopamine transmission in the NAc similar to wild-type mice, an effect absent in nonrescued b2 knockout mice (Maskos et al., 2005) . Moreover, wild-type and rescued b2 knockout mice demonstrated a preference for the arm of a Y-maze paired with the delivery of intra-VTA nicotine infusions upon arm entry. In contrast, nonrescued b2 knockout mice did not display a preference for either the nicotinepaired or nonpaired arm of the Y-maze (Maskos et al., 2005) . Additionally, Walters et al. (2006) found that b2 knockout mice do not demonstrate a conditioned place preference for an environment previously paired with nicotine injections. Furthermore, using b2 knockout mice, Shoaib et al. (2002) showed that b2* nAChRs regulate the discriminative stimulus properties of nicotine. The above observations suggest that b2 nAChR subunits play a central role in nicotine reinforcement, consistent with the high density of these subunits in the VTA and other reward-relevant brain regions.
In addition to gene knockout technology, Tapper the a4 nAChR gene was replaced in mice with one containing a single point mutation (Leu 9 0 -Ala 9 0 ). This point mutation renders mutant 'knock-in' a4-containing receptors hypersensitive to nicotine. Using these a4 knock-in mice, nicotine was shown to induce a significant conditioned place preference, a measure of the conditioned rewarding effects of drugs of abuse, at doses 50-fold lower than those necessary to induce a place preference in wild-type mice (Tapper et al., 2004) . These data suggest that, similar to b2 nAChR subunits, a4 subunits also likely are important regulators of nicotine reinforcement processes. Importantly, however, the role of a4 subunits in nicotine reinforcement has not yet been directly tested by intravenous nicotine self-administration behavior in a4 nAChR knockout mice.
In contrast to most other nAChR subunits expressed in the CNS, the a5 nAChR subunit does not form functional receptors when expressed alone or when coexpressed with b subunits in Xenopus oocytes (Ramirez-Latorre et al., 1996; Yu and Role, 1998) . Rather, the function of the a5 nAChR subunit is restricted to a modulatory role when incorporated into functional nAChRs, regulating the activation and desensitization kinetics and other characteristics of nAChRs (Girod et al., 1999; Nelson and Lindstrom, 1999) . Unfortunately, compounds selective for a5* nAChRs are not available. Therefore, in-vivo pharmacological data supporting a role for a5 subunits in nicotine self-administration have not been generated. Nevertheless, accumulating circumstantial evidence suggests that a5* nAChRs may play a key role in nicotine reward and dependence processes. As stated above, the a5 nAChR subunit is expressed at high concentrations in the VTA (Klink et al., 2001) , an important neuroanatomical substrate that regulates nicotine reward. Indeed, the a5 subunit is considered an important component of two putative functional nAChR subtypes expressed on VTA dopamine neurons (Klink et al., 2001) : a4a6a5(b2) 2 and (a4) 2 a5(b2) 2 . Furthermore, a5 knockout mice have decreased behavioral sensitivity to the effects of nicotine, measured by nicotine-induced seizures and hypolocomotion (Salas et al., 2003a) . The most convincing evidence supporting a role for a5* nAChRs in nicotine dependence has been generated from genetic analyses of human smokers. A nonsynonymous single nucleotide polymorphism in the a5 nAChR gene was associated with a two-fold increase in the risk of developing nicotine dependence in humans after they were exposed to cigarette smoking (Saccone et al., 2007) . Similarly, Schlaepfer et al. (2008) found that two linked single nucleotide polymorphisms on the gene cluster that incorporates the a3, a5, and b4 nAChR subunits predicted early-onset tobacco use in young adults. Berrettini et al. (2008) showed in three independent populations of human samples, totaling approximately 15 000 individuals, that a common genetic haplotype in the a3/a5/b4 gene cluster predisposes individuals to nicotine dependence. Recently, poly-morphism in the a3/a5/b4 gene cluster, most notably in the a5 nAChR subunit gene, predisposed smokers to increased risk of developing lung cancer (Hung et al., 2008) , perhaps by increasing the reinforcing effects of tobacco smoke, resulting in greater tobacco intake and associated carcinogens, and increased risk of developing cancer (Thorgeirsson et al., 2008) . Interestingly, polymorphism in the a5 nAChR subunit gene was found to be protective against cocaine dependence (Grucza et al., in press), a finding suggesting that nicotine and cocaine reinforcement may be dissociated at the level of a5* nAChRs. Taken together, these data suggest that the a5 nAChR subunit likely plays a critical role in nicotine dependence processes. Nevertheless, direct assessment of the reinforcing effects of nicotine in a5 knockout mice will be necessary to support this conclusion.
Much interest has centered on the potential role of a6 nAChR subunits in regulating nicotine reinforcement processes. This interest has arisen, in large part, because of the high concentrations and relatively restricted patterns of expression of mRNA transcripts for a6 subunits in the VTA (Quik et al., 2000; Azam et al., 2002; Champtiaux et al., 2002) . The expression of a6 nAChR subunits was shown to undergo robust upregulation in rats after repeated exposure to intravenous nicotine self-administration (Parker et al., 2004) . More recently, pharmacological data have emerged that further support a role for this subunit in nicotine reinforcement. Neugebauer et al. (2006) demonstrated that the novel nAChR antagonist bPiDDB, which may selectively antagonize a6* and/or a3* nAChRs (Dwoskin et al., 2004; Neugebauer et al., 2006) , dose-dependently decreases nicotine self-administration and the hyperactivity induced by acute and repeated nicotine administration in rats. Furthermore, Le Novere et al. (1999) demonstrated that knockdown of a6 mRNA through the use of antisense oligonucleotides attenuates the locomotor stimulatory effects of nicotine in mice. These data provide circumstantial evidence implicating a6-containing nAChRs in nicotine reinforcement processes, but the role of this subunit has not yet been directly tested.
The nAChR antagonist methyllycaconitine (MLA) is considered relatively selective for a7 pentameric nAChRs (Ward et al., 1990) , and a high concentration of a7 nAChRs exists in the VTA and other reward-related brain sites, including the amygdala (Seguela et al., 1993) . MLA was shown to attenuate the conditioned rewarding effects of nicotine after direct intra-VTA administration in rats (Laviolette and van der Kooy, 2003) . Furthermore, intra-VTA administration of MLA attenuated the ICSS threshold-lowering effects of nicotine in rats . More importantly, Markou and Paterson (2001) demonstrated that MLA decreased intravenous nicotine self-administration in rats. These observations suggest that a7 nAChRs play a role in nicotine reinforcement. In contrast, Grottick et al. (2000) demonstrated that MLA did not alter nicotine self-administration or nicotinestimulated locomotor activity in rats. On the basis of these findings, a7 nAChRs were speculated to play no role in regulating nicotine reinforcement (Grottick et al., 2000) . Consistent with this conclusion, nicotine was shown to elicit a conditioned place preference in a7 mice that was very similar to that observed in wild-type mice (Walters et al., 2006) . Thus, the precise role of a7 nAChRs in nicotine reinforcement remains unclear, and testing of a7 knockout mice in the intravenous nicotine selfadministration procedure may provide important insights into the role of this receptor subunit in nicotine reinforcement. Overall, the above data support a role for a4 and b2, and perhaps a5, a6, and a7, nAChR subunits in regulating the positive reinforcing effects of nicotine. In addition, these data demonstrate the utility of nAChR knockout mice for investigating the nAChR subtypes that regulate nicotine reinforcement.
Nicotinic acetylcholine receptor subunits regulate the positive reinforcing effects of other drugs of abuse
Accumulating evidence suggests that nAChRs may play a role in the reinforcing effects of drugs of abuse other than nicotine, such as cocaine and alcohol. Cue-induced cocaine craving is potentiated by nicotine pretreatment in human cocaine users whom are also cigarette smokers (Reid et al., 1998) . In rats, the development of escalated levels of cocaine intake that is associated with extended daily access to the drug was abolished by coadministration of the nAChR antagonist mecamylamine (Hansen and Mark, 2007) . This observation suggests that nAChRs may regulate the development of compulsive cocaine-seeking. Perfusion of mecamylamine or coperfusion of the nAChR antagonists DHbE and MLA into the NAc blocked the stimulatory effects of cocaine on NAc dopamine release (Zanetti et al., 2007) . More importantly, b2 knockout mice appear to be less sensitive to the conditioned rewarding effects of cocaine (Zachariou et al., 2001) . Furthermore, induction of chronic Fos-related antigens by cocaine, which may contribute to cocaine-associated neuroplasticity, was abolished in b2 knockout mice compared with wild-type siblings, implying that the actions of cocaine downstream of membrane-expressed receptors may be regulated by b2* nAChRs (Zachariou et al., 2001) .
In addition to cocaine, nAChRs play a role in alcohol dependence. In human populations, polymorphisms in the a3/a5/b4 nAChR gene cluster were associated with increased vulnerability to alcoholism (Schlaepfer et al., 2008; Wang et al., in press) , as well as with altered steadystate levels of a5 nAChR mRNA in the brain (Wang et al., in press). Mecamylamine decreased the desire to consume alcohol in humans (Young et al., 2005) and blocked the self-reported euphoric effects of alcohol (Chi and De Wit, 2003) . In rats, mecamylamine decreased ethanol intake (Blomqvist et al., 1996; Ericson et al., 1998; Le et al., 2000) and attenuated the stimulatory effects of ethanol on dopamine release in the NAc when administered either systemically (Blomqvist et al., 1993) or directly into the anterior, but not posterior, VTA (Ericson et al., 2008) . Systemic or direct intra-NAc administration of mecamylamine decreased ethanol consumption by rats (Nadal et al., 1998; Le et al., 2000) . Similarly, the a4b2* nAChR partial agonist varenicline was shown recently to decrease ethanol consumption by rats (Steensland et al., 2007) . Interestingly, chronic ethanol consumption decreased the expression of a7 and a4b2* nAChRs in the hippocampus (Robles and Sabria, 2008) . Patch-clamp recordings from human embryonic kidney cells that heterologously express human nAChR subunits have shown that ethanol can act directly at nAChRs to potentiate the activity of a4* nAChRs (Zuo et al., 2001 (Zuo et al., , 2002 . These data suggest that nAChRs play a role in the neurochemical actions of alcohol that participate in the regulation of alcohol intake. Interestingly, a7 knockout mice are more sensitive than wild-type mice to some of the behavioral actions of ethanol, including ethanolinduced locomotor stimulation and loss of righting reflex . However, little is known about the reinforcing effects of alcohol in a7* knockout and other strains of nAChR knockout mice. Taken together, the above data support an important role for nAChRs, particularly those containing b2 subunits but perhaps also a5 and a7 subunits, in the reinforcing actions of cocaine and alcohol, as well as in the neuroplasticity induced by these drugs that may contribute to compulsive drug-seeking.
Nicotinic acetylcholine receptor subunits in nicotine dependence and withdrawal
Addiction to tobacco smoking depends not only on the positive reinforcing and hedonic actions of nicotine, but also on escape from the aversive consequences of nicotine withdrawal (Doherty et al., 1995; Kenny and Markou, 2001) . Indeed, prolonged nicotine exposure results in the development of nicotine dependence, and smoking cessation commonly elicits an aversive nicotine withdrawal syndrome in human smokers (Shiffman and Jarvik, 1976; Hughes et al., 1991) . This syndrome can be directly attributed to a reduction of nicotine intake in nicotinedependent individuals (West et al., 1984) . Importantly, withdrawal duration and severity can predict relapse in abstinent human smokers (Piasecki et al., 1998 (Piasecki et al., , 2000 (Piasecki et al., , 2003 . Furthermore, the efficacy of nicotine replacement therapy, at least in certain individuals (Fagerstrom, 1988; Sachs and Leischow, 1991) , is related to its ability to nAChRs and nicotine dependence Fowler et al. 471 prevent the onset and reduce the duration of nicotine withdrawal. Isola et al. (1999) have shown that spontaneous or mecamylamine-precipitated withdrawal from chronic nicotine injections (2 mg/kg salt, four times daily for 14 days) resulted in increased expression of physical or 'somatic' withdrawal signs (e.g. rearing, jumping, shakes, abdominal constrictions, chewing, scratching, facial tremor) in mice. Similarly, spontaneous or antagonistprecipitated withdrawal from nicotine delivered through osmotic minipump (24-48 mg/kg/day free-base, 7 to 60day continuous treatment) also increased somatic withdrawal signs, and these signs were increased by a greater magnitude in C57BL/6 than in 129/SvEv strains of mice (Damaj et al., 2003) . This strain difference is important to note because most nAChR knockout mice are bred on a C57BL/6 background. Besson et al. (2006) have shown that somatic withdrawal signs were increased by a similar magnitude in wild-type and b2 knockout mice during mecamylamine-precipitated withdrawal from nicotine delivered through osmotic minipump (2.4 mg/kg/day free-base, 28 days continuous treatment). The a7selective nAChR antagonist MLA increased somatic withdrawal signs in wild-type and b2 knockout mice after chronic nicotine treatment (24-36 mg/kg/day freebase through osmotic minipump, 13-28 days continuous treatment) (Salas et al., 2004; Jackson et al., 2008) . Under similar treatment conditions, however, somatic withdrawal signs were diminished in a5, a7, and b4 knockout mice (Salas et al., 2004 (Salas et al., , 2007 Jackson et al., 2008) . On the basis of the above observations, a5, a7, and b4, but not b2, subunits are likely components of the nAChRs that regulate the development of physical dependence on nicotine and the expression of somatic withdrawal signs.
Affective components of nicotine and tobacco withdrawal include depressed mood, dysphoria, anxiety, irritability, difficulty in concentrating, and craving (Parrott, 1993; Doherty et al., 1995; Kenny and Markou, 2001) . Accumulating evidence suggests that affective components of withdrawal may play a more important role than somatic aspects in the maintenance of dependence to drugs of abuse, including nicotine Kenny and Markou, 2001; George et al., 2007) . In mice, withdrawal from nicotine delivered through osmotic minipump (Damaj et al., 2003; Jonkman et al., 2005) or repeated daily injections (Costall et al., 1989 ) increased the expression of anxiety-like behaviors. Similarly, the time spent immobile in the forced swim test, considered an index of depression-like behavior, was increased in mice undergoing withdrawal from nicotine (2 mg/kg, four injections daily for 15 days) compared with saline-treated controls (Mannucci et al., 2006) . Recent findings in nAChR knockout mice have provided insights into the nAChR subunits that may regulate affective aspects of nicotine withdrawal. Affective signs of spontaneous or mecamylamine-precipitated nicotine withdrawal (36 mg/ kg/day through an osmotic minipump for 14 or 28 days), reflected in increased anxiety-related behavior and induction of a conditioned place aversion, were absent in b2 knockout mice but were readily observed in a5 knockout and a7 knockout mice (Jackson et al., 2008) . Furthermore, the deficits in fear conditioning typically observed in mice undergoing withdrawal from nicotine (6.3 mg/kg/day free-base via osmotic minipump, 12 days treatment) were intact in a7 knockout mice but were greatly diminished in b2 knockout mice (Portugal et al., 2008) . Therefore, b2*, but not a5* or a7*, nAChRs may contribute to the affective components of the nicotine withdrawal syndrome.
Withdrawal from nicotine and other major drugs of abuse decreases brain reward function, reflected in elevated ICSS thresholds in rats (Epping-Jordan et al., 1998; Watkins et al., 2000; Kenny and Markou, 2005) . Such reward deficits are considered a particularly important affective component of withdrawal that maintains drugtaking behavior (Koob and Le Moal, 2005; Kenny, 2007) . Systemic administration of the nAChR antagonist DHbE, but not MLA, precipitated withdrawal-associated elevations of ICSS thresholds in nicotine-dependent rats (3.16 mg/kg/day for 7-14 days) (Ivanova and Greenshaw, 1997; Markou and Paterson, 2001; Harrison et al., 2002) . Infusion of DHbE into the VTA also precipitated elevations of ICSS thresholds in nicotine-dependent, but not control, rats (Bruijnzeel and Markou, 2004) . As stated above, DHbE is relatively selective for a4* and b2* nAChRs . Therefore, these data provide pharmacological support for a role of a4* and b2* nAChR subtypes, particularly those located in the VTA, in regulating the development of nicotine dependence and the expression of nicotine withdrawal. Nevertheless, the role of these or other nAChR subunits in regulating the reward deficits associated with nicotine withdrawal has not been directly tested in nAChR knockout mice. Recent data from our laboratory have, however, shown that nicotine withdrawal does indeed elevate ICSS thresholds in mice, similar to rats, highlighting the potential utility of the ICSS procedure for assessing nicotine withdrawal-associated reward deficits in nAChR knockout mouse strains (Johnson et al., 2008) .
Finally, in a series of interesting studies, Nashmi et al.
(2007) generated genetically modified mice in which the a4 nAChR subunit was altered to express a fluorescent tag [yellow fluorescent protein (YFP)], and these mice were used to assess the effects of chronic nicotine administration on the expression of a4* nAChRs in cell populations located in the VTA (Nashmi et al., 2007) . The a4*-YFP mice were treated continuously for 10 days with nicotine (48 mg/kg/day) via osmotic minipump. Levels of a4-YFP in VTA dopaminergic cells were not significantly altered by chronic nicotine exposure. In contrast, a4-YFP levels were dramatically increased in GABAergic cells in the VTA. A similar increase in a4-YFP expression in VTA GABAergic cells was also observed in mice chronically treated with a lower dose of nicotine (9.6 mg/kg/day). These data demonstrate that VTA cell populations are differentially sensitive to nicotine-induced plasticity in a4* nAChR expression and suggest that a4* nAChRs located in VTA GABAergic cells may be a particularly important target for the induction of nicotine dependence (Nashmi et al., 2007) .
Anxiety disorders and subtypes of nicotinic acetylcholine receptors
Anxiety has been defined as an emotional condition characterized by an unpleasant and diffuse sense of apprehension usually accompanied by autonomic symptoms, such as headache or palpitations (Millet et al., 1998) . Anxiety is distinguished from fear by the fact that in anxiety a threat generated 'internally' results in an emotional response, whereas in the case of fear, the threat is external and known. In humans, anxiety disorders encompass a number of related conditions, including generalized anxiety disorder, panic disorder, phobia, obsessive-compulsive disorder, and posttraumatic stress disorder (American Psychiatric Association, 1994) . Many pharmacological agents used to treat anxiety disorders, including fluoxetine (Prozac; Eli Lilly and Company, Indiana, USA) or buspirone (Buspar; Bristol-Myers Squibb, New Jersey, USA), have direct actions on nAChRs (Dilsaver and Davidson, 1987; Fryer and Lukas, 1999; Hennings et al., 1999; Lopez-Valdes and Garcia-Colunga, 2001; Miller et al., 2002; Garwood and Potts, 2007) , suggesting a role of nAChR modulation in the therapeutic actions of these compounds. A high prevalence of tobacco addiction exists among individuals who suffer from anxiety disorders (Koenen et al., 2006; Morissette et al., 2007; Goodwin et al., 2008) . Indeed, Hughes et al. (1986) reported that the incidence of smoking was approximately 47% in patients suffering from an anxiety disorder compared with 30% in control patients. Patients suffering from obsessive-compulsive disorder may, however, have reduced rates of tobacco dependence compared with the general population (Bejerot and Humble, 1999; Lopes et al., 2002) . Many smokers report that cigarettes have an anxiety-reducing influence (Speilberger, 1986) and that mood control is a core reason for maintaining their smoking habit (Parrott, 1994) . Conversely, smoking abstinence and associated nicotine withdrawal is known to increase subjective levels of anxiety in smokers (Hughes et al., 1991) . Thus, nicotine in tobacco smoke seems to have subjective anxiolytic effects that are important in maintaining the tobacco habit and may be particularly important in individuals with comorbid anxiety disorders. Neverthe-less, the precise relationship between nicotine consumption and anxiety state is unclear. Although accumulating evidence suggests that nicotine in tobacco smoke may have subjective anxiety-reducing properties, nicotine itself actually may contribute to the development of anxiety disorders (West and Hajek, 1997; Isensee et al., 2003) . Taken together, the above observations are consistent with the notion that deficits may exist in nAChR signaling pathways in the brains of smokers who suffer from comorbid anxiety disorders, and these deficits may enhance the reinforcing effects of nicotine and result in higher rates of tobacco dependence in such individuals.
In rodents, acute administration of nicotine or nAChR agonists has complex actions on anxiety-related behaviors (Brioni et al., 1993; Kenny et al., 2000a) . Nicotine can increase or decrease anxiety-like behaviors in rats, depending on the dose of nicotine and the baseline state of anxiety-like behavior at testing (File et al., 1998b) . Similarly, nAChR antagonists also have complex actions on anxiety-like behavior (File et al., 1998a; Newman et al., 2001 Newman et al., , 2002 . This complexity likely reflects populations of nAChRs located in different neurotransmitter systems in the brain that have opposing actions on anxiety behaviors (for reviews, see File et al., 2000a, b) . Consistent with this interpretation, administration of nicotine into the dorsal hippocampus increased anxiety-like behaviors in rats, and this effect was blocked by coadministration of the a7* nAChR-selective antagonist MLA (Tucci et al., 2003) . Conversely, nicotine administered into the dorsal raphe nucleus decreased anxiety-like behaviors in rats, and this effect was abolished by DHbE (Cheeta et al., 2001a, b) . Interestingly, a7 knockout mice were shown to spend significantly more time in the center of an open-field apparatus than wild-type controls, suggesting that a7 knockout mice may have reduced levels of anxiety (Paylor et al., 1998) . Importantly, however, Salas et al. (2007) did not observe any difference in anxiety-like behaviors between a7 knockout mice and wild-type controls. Recent data suggest that b3 nAChR knockout mice may display reduced anxiety-like behaviors compared with wild-type mice, reflected in more time spent on the open arm of an elevated plus-maze compared with wild-type littermates (Booker et al., 2007) . b4 knockout mice also displayed decreased anxiety-like behaviors on an elevated plus-maze and staircase maze compared with wild-type mice (Salas et al., 2003b) . The reduction in anxiety-like behaviors in b4 knockout mice compared with wildtype mice on the elevated plus maze was supported by telemetry measures of heart rate; the b4 knockout exhibited lower increases in heart rate than controls (Salas et al., 2003b) . Therefore, these data suggest a role for the b3* and b4* nAChRs in anxiety-like behaviors in mice. In contrast to b3 and b4 knockout mice, a4 knockout mice were shown to spend significantly less time on the open arm of an elevated plus-maze apparatus nAChRs and nicotine dependence Fowler et al. 473 than wild types (Ross et al., 2000) , suggesting that a4 knockout mice may have an anxiogenic-like phenotype. Paradoxically, mice with a point mutation in the a4 nAChR subunit gene, which renders a4* nAChRs hypersensitive, also exhibited increased anxiety-like behaviors compared with wild-type controls (Labarca et al., 2001) . Finally, anxiety-like behaviors were unaltered relative to wild-type controls in mice simultaneously lacking both the a7 and b2 nAChR subunits, although these mice exhibited deficits in a test of fear-based learning (Marubio and Paylor, 2004) . These behavioral genetics data suggest that b3 nAChR subunits, and perhaps a7 and a4 subunits, may regulate anxiogenic-like actions of endogenous cholinergic transmission in the brains of mice. Furthermore, these observations highlight the complex and sometimes contradictory nature of nAChR modulation of anxiety states.
In common with abstinent human tobacco smokers, nicotine withdrawal elicits an anxiogenic-like state in rodents (Cheeta et al., 2001a; Irvine et al., 2001a, b; Biala and Weglinska, 2005; Jonkman et al., 2005) . The nAChR antagonist DHbE increases anxiety-like behaviors in nicotine-dependent mice (Damaj et al., 2003) . b2 knockout mice do not show the decreased time spent on the open arm of an elevated plus-maze (i.e. increased anxiety-like behavior) usually observed in wild-type mice during mecamylamine-precipitated nicotine withdrawal (Jackson et al., 2008) . Importantly, nicotine withdrawal elicits an increase in anxiety-like behavior in a5 and a7 knockout mice that is similar to the magnitude observed in wild-type mice (Jackson et al., 2008) , suggesting that these nAChR subunits are not involved in the expression of nicotine withdrawal-associated increases in anxietylike behaviors. Thus, a4* and b2*, but not a5* nor a7*, nAChRs likely regulate the anxiogenic-like state associated with nicotine withdrawal.
Finally, increased activity of the hypothalamic-pituitaryadrenal axis (HPA) may play an important role in the etiology of anxiety disorders as well as depression and schizophrenia. Accumulating evidence indicates that nAChRs regulate HPA function, possibly by modulating corticotropin-releasing factor (CRF) and corticosterone levels. Axon terminals in the median eminence seem to contain CRF-like immunoreactive synaptic vesicles and membrane-bound nAChRs (Okuda et al., 1993) . In rats, nicotine administered systemically or by self-administration acutely increased plasma levels of corticosterone and adrenocorticotropic hormone (Cam and Bassett, 1983; Chen et al., 2008) , whereas chronic self-administration decreased CRF mRNA expression in the paraventricular nucleus (Yu et al., 2008) . Mecamylamine-precipitated nicotine withdrawal enhanced anxiety-associated behaviors and CRF-like immunoreactivity in the amygdala, likely through CRF 1 receptors (George et al., 2007) , and CRF antagonism prevented, but could not reverse, the elevation of ICSS brain reward thresholds found during mecamylamine-precipitated nicotine withdrawal (Bruijnzeel et al., 2007) . The nAChR subtypes that participate in the regulation of these effects on the HPA are unclear. Interestingly, however, b3 knockout mice had increased basal and stress-induced corticosterone levels compared with wild-type controls (Cui et al., 2003; Booker et al., 2007) , suggesting increased stress responsiveness. Previously, systemic corticosterone administration was shown to reduce anxiety-like behavior in rats (File et al., 1979) , possibly through feedback inhibition of stress cascades in the brain. Thus, the lower levels of anxiety-like behavior observed in b3 knockout mice may be secondary to increased anxiety-reducing corticosterone levels. Further, these data implicate the b3* nAChR or non-b3* nAChRs that have undergone adaptation in the b3 knockout mice, in regulation of the HPA system.
Depression and subtypes of nicotinic acetylcholine receptors
In humans, major depression often is comorbidly expressed with tobacco addiction, similar to the relationship described above between tobacco smoking and anxiety disorders (Breslau, 1995; Diwan et al., 1998) . Human tobacco smokers are more likely than the general population to display symptoms of depression and to be diagnosed with major depression (Covey et al., 1997; Laje et al., 2001) . Nicotine is reported to have mood-enhancing effects in smokers (Foulds et al., 1997) , whereas cessation of the tobacco habit can precipitate depressionlike systems in smokers (Glassman et al., 1990) . Many antidepressant agents that are used to treat major depression can potently antagonize nAChRs (Fryer and Lukas, 1999; Miller et al., 2002; Shytle et al., 2002) , and this action may contribute to their therapeutic effects. Thus, cigarette smoking may represent a form of selfmedication behavior in depressed individuals in which the nicotine contained in tobacco smoke may induce antidepressant or other beneficial effects (Rabenstein et al., 2006) .
Selective serotonin reuptake inhibitors and tricyclic antidepressants can increase limbic serotonin (5-hydroxytryptamine) transmission, and this action is hypothesized to contribute to their antidepressant actions. Additionally, antidepressants also increase the expression of brainderived neurotrophic factor (BDNF) in limbic brain regions, and this action may also contribute to the therapeutic utility of these agents (Nibuya et al., 1996; Duman et al., 1997) . Consistent with an antidepressantlike action of nicotine, earlier studies have shown that nicotine increases the release of serotonin from superfused hippocampal slices . Furthermore, chronic nicotine exposure increased BDNF mRNA in the hippocampus of rats (Kenny et al., 2000c) , whereas nicotine withdrawal decreased hippocampal BDNF mRNA expression (Kenny et al., 2000c) . These effects of nicotine could potentially contribute to the subjective mood-enhancing effects of the drug in human smokers, as well as the negative affect associated with nicotine withdrawal. Intriguingly, mecamylamine also increases hippocampal serotonin release similar to the stimulatory effects of nicotine , and also has antidepressant-like effects in animals Rabenstein et al., 2006) . Indeed, both nicotine and nAChR antagonists can potentiate the antidepressantlike effects of tricyclic antidepressant drugs in mice (Popik et al., 2003) . These observations likely reflect preferential actions of nicotine and mecamylamine at different populations of nAChRs that have opposing actions, similar to the scenario described above for nAChR modulation of anxiety-like behaviors. Such an explanation would account for the apparently contradictory findings in which both an agonist (nicotine) and antagonist (mecamylamine) at nAChRs can elicit similar neurochemical and behavioral effects.
Neurogenesis is the process by which new cells are born and mature into functional neurons and occurs in the adult mammalian brain (Fowler et al., 2008) . Neurogenesis in the hippocampus is potentiated by antidepressant treatment, likely through a mechanism involving hippocampal serotonin and BDNF transmission, and is hypothesized to play a role in the therapeutic efficacy of antidepressant drugs (Brezun and Daszuta, 1999; Gould, 1999; Brezun and Daszuta, 2000; Lee et al., 2000; Duman et al., 2001; Pencea et al., 2001; Katoh-Semba et al., 2002; Santarelli et al., 2003; Mattson et al., 2004; Sairanen et al., 2005) . In vitro, nicotine appears to be cytotoxic to newly born neurons by inducing apoptosis of hippocampal progenitor cells . Similarly, in vivo, intravenous nicotine self-administration decreased neurogenesis in the hippocampus of adult rats (Abrous et al., 2002) . However, it is worth noting that in this study rats were euthanized 48 h after the last self-administration session; thus, these observations may be more indicative of nicotine withdrawal rather than the primary actions of nicotine. More recently, the proliferation of newly born cells was shown to be significantly reduced in the hippocampus of b2 knockout mice compared with wildtype controls , suggesting that constitutive cholinergic transmission at b2* nAChRs may promote hippocampal neurogenesis. Thus, nAChRs seem to regulate hippocampal neurogenesis in a complex manner, and this regulation may contribute to the multifaceted effects of nicotine on mood.
Emerging evidence from nAChR knockout mice supports the hypothesis that nAChRs play a central role in mood regulation and in gating the beneficial actions of antidepressant drugs. In the learned helplessness test, wild-type mice were shown to respond to the antidepressant-like effects of the tricyclic antidepressant amitriptyline . In contrast, these beneficial effects of amitriptyline were absent in b2 knockout mice. Similarly, the antidepressant-like effects of amitriptyline observed in wild-type mice tested in the tail suspension and forced swim tests were absent in b2 knockout mice . In addition to the key role noted above for b2* nAChRs in regulating the stimulatory effects of endogenous cholinergic transmission on hippocampal neurogenesis , b2* nAChRs also seem to regulate the stimulatory effects of antidepressants on this process. Indeed, the stimulatory effects of amitriptyline on cell proliferation observed in the adult hippocampus of wild-type mice were absent in b2 knockout mice . Most recently, Rabenstein et al. (2006) demonstrated that the antidepressant-like effects of mecamylamine in wild-type mice were absent in b2 knockout or a7 knockout mice, measured in the tail suspension test. These data provide further support for a role of nAChRs in the beneficial effects of antidepressants.
Taken together, the above data demonstrate that nAChRs may play a key role in regulating baseline affective state and the beneficial effects of antidepressant drugs. The observation that hippocampal neurogenesis is impaired in b2 knockout mice supports the hypothesis that constitutive deficits in nAChR signaling cascades may contribute to vulnerability to depression and other mood disorders and may also contribute to the increased motivation to consume nicotine in tobacco smoke in humans.
Schizophrenia and subtypes of nicotinic acetylcholine receptors
Approximately 1% of the population of the United States, around 2 million people, suffer from schizophrenia (Rupp and Keith, 1993) . Similarly to anxiety disorders and depression, the rate of tobacco smoking is dramatically higher in schizophrenia patients compared with the general population (Masterson and O'Shea, 1984; Hughes et al., 1986; Goff et al., 1992; Dalack et al., 1998) . Estimates indicate that the prevalence of tobacco smoking in schizophrenia patients is between 60 and 90%. Several explanations have been proposed to account for the high incidence of tobacco use in schizophrenia patients. First, this high rate may reflect an attempt by schizophrenia patients to reduce neuroleptic-induced extrapyramidal side-effects (Jarvik, 1991) . Second, the nicotine obtained from tobacco smoke may ameliorate the generalized cognitive or sensory gating deficits associated with schizophrenia (Curzon et al., 1994; Acri et al., 1995; Kumari et al., 1996; Kumari and Gray, 1999) . Third, the rewarding properties of nicotine may be increased in schizophrenia patients, resulting in greater abuse potential (Chambers et al., 2001; Spring et al., 2003) . Finally, nicotine obtained through tobacco smoking may nAChRs and nicotine dependence Fowler et al. 475 ameliorate the negative symptoms of schizophrenia (Markou and Kenny, 2002; Cook et al., 2007) . A combination of the aforementioned factors likely contributes to the increased motivation to consume nicotine in tobacco smoke in human schizophrenia patients and to the beneficial effects that nicotine has on various symptoms of schizophrenia (Glynn and Sussman, 1990; Dalack and Meador-Woodruff, 1996) .
Accumulating evidence from human patient populations suggests that a genetic linkage may exist between symptoms of schizophrenia and polymorphisms in nAChR subunits (Freedman et al., 2001; Leonard et al., 2002; De Luca et al., 2006) , particularly the a7 nAChR subunit. Indeed, abnormal sensory gating in schizophrenia has been associated with polymorphisms in chromosome 15q13-14, which encompasses the a7 nAChR gene locus (Freedman et al., 1997) . Nicotine has been reported to improve sensory gating and attention in patients with schizophrenia (Depatie et al., 2002) . a7 nAChR knockout mice display deficits in working memory and attention Young et al., 2007) . a7 nAChR knockout mice also have marked deficits in the acquisition of an operant response to obtain food rewards, suggesting that associative learning processes may be disrupted in a7 nAChR knockout mice . Similar cognitive deficits also are observed in rats following antisense-mediated knockdown of a7 nAChR subunits (Curzon et al., 2006) . Consistent with a role for a7* nAChRs in cognition, the nAChR partial agonist SSR180711 enhances episodic memory in wild-type but not in a7 knockout mice (Pichat et al., 2007) . Furthermore, viral-mediated overexpression of a7 nAChR subunits in the mouse hippocampus improves spatial memory (Ren et al., 2007) . As a7 receptors are highly expressed in the hippocampus (Seguela et al., 1993) , and decreased nicotinic receptor density is found in the hippocampus in schizophrenia patients (Freedman et al., 1995) , the above data suggest that the cognitive deficits associated with schizophrenia may at least partly arise through decreased a7* nAChR signaling. The high rates of smoking in schizophrenia patients may reflect high motivation to obtain the stimulatory effects of nicotine on a7* nAChRs, thereby improving compromised cognitive performance.
In addition to a7* nAChRs, accumulating evidence generated from knockout mice supports a role for other nAChR subunits in the neuropathology associated with schizophrenia. b3 nAChR knockout mice have deficits in prepulse inhibition (PPI) compared with wild-type mice (Cui et al., 2003) . PPI is the process by which a weaker prepulse stimulus can attenuate the reaction of an organism to a subsequent stronger startling stimulus. Deficits in PPI likely reflect abnormalities in sensorimotor gating and are manifested in individuals who suffer from schizophrenia (Braff et al., 2001) . Interest-ingly, b3 knockout mice have higher constitutive levels of striatal dopamine transmission in response to cholinergic (nicotinic receptor) stimulation, possibly reflecting compensatory increases in the function of non-b3* nAChRs in response to b3 nAChR subunit null mutation (Cui et al., 2003) . Importantly, enhanced striatal dopamine-mediated transmission may contribute to the sensorimotor gating deficits observed in schizophrenia patients (Braff and Geyer, 1990) . Thus, an interesting possibility is that deficits in b3* nAChR signaling cascades or compensatory alterations in non-b3* nAChRs may contribute to the sensorimotor gating deficits in schizophrenia. nAChRs are also found in glutamate-containing terminals throughout the brain, including the prefrontal cortex (Jones and Wonnacott, 2004) . Nicotine or acetylcholine increases glutamate-mediated transmission in prefrontal cortical slices, and this action is absent in b2 knockout mice (Lambe et al., 2003) . On the basis of the fact that the prefrontal cortex is an important brain region in schizophrenia-associated neuropathology, deficits in b2* nAChRs in the prefrontal cortex have been hypothesized to contribute to schizophrenia-associated cognitive and behavioral deficits (Lambe et al., 2003) .
Conclusion and future directions
As can be seen from the data reviewed above, mice with genetic modifications in discrete nAChR subunits serve as powerful tools that can increase our understanding of the subunit composition of the nAChRs that regulate the rewarding properties of nicotine and also that regulate the development of nicotine dependence and expression of nicotine withdrawal. nAChR knockout mice have provided strong evidence that a4* and b2* nAChR subunits are critically involved in the rewarding effects of nicotine. Furthermore, based on data from nAChR knockout mice, b2*, but not a5* or a7*, nAChRs may contribute to the affective components of nicotine withdrawal. Conversely, a5*, a7*, and b4*, but not b2*, nAChRs may contribute to the somatic aspects of nicotine withdrawal.
In addition to their utility in delineating the mechanisms of nicotine reward and dependence, nAChR mutant mice are providing important insights into the contribution of nAChRs to psychiatric illnesses, as well as to the mechanisms that may contribute to the increased incidence of tobacco dependence associated with many psychiatric disorders. nAChR knockout mice have provided evidence that a4*, a7*, and b3* nAChRs may play an important role in anxiety-related disorders. b2* and a7* nAChRs may regulate the mood-enhancing effects of antidepressant drugs and also may regulate baseline affective state. Studies in nAChR knockout mice suggest that a7* and perhaps b2* and b3* nAChRs may regulate expression of various symptoms of schizophrenia.
Many important aspects of the mechanisms by which nAChRs regulate nicotine addiction processes and contribute to psychiatric illness remain to be resolved. For example, what is the precise subunit composition of the nAChR subtypes in vivo that regulate tobacco addiction? If addiction-related subpopulations of nAChRs can be identified, will selective modulation of their activity be possible, independent of other populations of nAChRs that are involved in essential neurophysiological processes? Finally, what are the signaling mechanisms through which addiction-associated nAChRs regulate behavior? Considering the progress that has been made to date using genetically modified mice, continuing advances in this field are expected to provide answers to these important questions.
